435 mmol/kg b.w.) of styrene. DNA adducts were analysed by the modified 32 Ppostlabelling assay and A'-terminal valine adducts were detected by GC-MS according to the modified Edman degradation technique. In the dose-range studied, for all adducts a clear dose-response relationship was observed. 7-Alkylguanines and 0 6 -styrene guanine adducts were most abundant in lungs, -30% more than in liver and spleen. In all analysed tissues 7-alkylguanines were more abundant than O'-styrene guanine adducts. We found a considerably lower rate of AMenninal valine adduct formation as compared with both DNA adducts. The ratio between 7-alkylguanines and O 6 -guanine adducts was 1.9, 1.6 and 7.8 in liver, lung and spleen, respectively. In vitro determination of both DNA adducts by 32 P-postlabelling resulted also in a lower ratio than that reported earlier using an HPLC analysis. All correlation's between dose, haemoglobin and DNA adducts were very high and significant. However, at the highest injected doses the adduct formation showed a levelling off. To explain this phenomenon a model simulation was performed revealing that 3 h after the injection of the higher doses styrene was not completely converted into styrene-7,8-oxide.
Introduction
Styrene is an important monomer in the production of plastics and synthetic rubbers world-wide. Styrene represents also an environmental contaminant and in small quantities is present in food items, tobacco smoke, and engine exhausts (1). In humans styrene is metabolized to styrene-7,8-oxide, which is a direct acting mutagen and carcinogen (1).
The main binding sites of styrene oxide in DNA are positions N-l, U 1 and O 6 of guanine (2, 3) . The proportions of N-1-, M 1 -and C^-adducts in double-stranded DNA are 74:22.3:3.7 after in vitro incubation (3) .
At present only the 32 P-postlabelling technique seems to
•Abbreviations: AUC, area under the curve; b.w., body weight; GC-MS, gas chromatography-mass spectrometry; HPLC, high pressure liquid chromatography; i.p., intraperitoneally; PBPK/model, physiologically based pharmacokinetic model; SEM, standard error of the mean; PEI TLC, polyethylene imine thin layer chromatography; SO, styrene oxide.
© Oxford University Press exhibit the sensitivity required for the quantitative determination of DNA adducts in vivo. Recent advances in 32 P-postlabelling methodology have enabled die specific detection of all main styrene-guanine DNA adducts (N-1-, O 6 -and N 2 -) in vitro and in vivo (4) (5) (6) (7) (8) . Moreover, O 6 -and A^-styrene specific guanine DNA adducts have been detected in humans occupationally exposed to styrene (4) (5) (6) (7) .
Adduct formation with haemoglobin, albumin, and DNA has been demonstrated in animals treated with styrene and styrene oxide (9) (10) (11) (12) (13) (14) . Styrene oxide covalently bound to haemoglobin is usually detected by analysing the adducts on A'-terminal valine and cysteine (15, 16) .
The fact that macromolecular adducts provide not only an estimate of the exposure to a genotoxic compound but also an indication of their potential mutagenic risk underlines the importance of investigations in this field. It has recently been suggested that sufficient data on styrene DNA binding in animals are virtually missing (17) .
The first aim of this study was to demonstrate the DNA and haemoglobin adduct formation related to i.p. administered doses of styrene in mice. Another objective was to study the ratio of DNA adduct formation between different tissues and the different target positions.
DNA adducts represent the most direct measure for the biologically effective dose of a potential carcinogen. However, haemoglobin adducts have been suggested as a good alternative due to the easy access to sufficient amounts of haemoglobin in blood samples. The use of haemoglobin adducts for the assessment of the genotoxic potential of an agent is based on the existence of a constant ratio between the reaction with tissue DNA and haemoglobin over a wide range of doses (18) .
A last objective was, therefore, to determine the ratio of adduct formation between haemoglobin and DNA adducts in the animals treated with styrene.
Materials and methods

Animal experiments
Styrene (98% pure, stabilized with 15 p.p.m. 4-rm-butylcatechol, UCB, Belgium) was mixed with dimethylsulphoxide (Merck, analytical grade) and com oil (2:1:9) immediately prior to i.p. injection to young white male NMRI mice (Charles River, Germany, 25-30 g). Seven mice were injected each with a different dose of styrene (range 0-4.35 mmol/kg b.w.). After 3 h, mice were anaesthetized with Nembutal (Sanofi, Belgium). Blood was collected by cardiac puncture and haemoglobin was immediately isolated as described by Severi et al. (19) . Liver, spleen, and lungs were excised and immediately frozen at -20°C until further analysis.
Haemoglobin analysis
Isolation of haemoglobin. The analysis of haemoglobin adducts was done essentially as described by Severi et al. (19) , based on the modified Edman degradation technique (15) . Red blood cells were separated by centnfugation at 3000 r.p.m. for 10 min. After repeated washing (three times) with saline the cells were lysed by the addition of 1 vol. of distilled water. Globin was isolated according to Mowrer et al. (20) . Hydrochloric acid (50 mM), in 2-propanol, was added and the mixture was centrifuged at 3000 r.p.m. for 10 min. Globin was precipitated by the addition of ethyl acetate. After filtration, globin was washed with ethyl acetate (twice) and pentane (twice) and then dried under a gentle air stream. Derivatization. About 50 mg of the globin was dissolved in 1.5 ml of formamide containing a known amount of deuterated internal standard, obtained through the reaction of haemoglobin with deuterated styrene-dg_7,8-oxide. Styrene-dg_7,8-oxide was prepared according to the method of Imuta and Ziffer (21) . The pH was adjusted by the addition of 30 (il sodium hydroxide (1 M). Aliquots of 15 Hi of the derivatization agent pentafluorophenyl isothiocyanate (Fluka, Buchs, Switzerland) were added and the reaction mixture was shaken overnight. The derivatization was completed at 45°C for 90 min. Subsequently the derivative was extracted from the medium with diethyl ether (three times). The ether extracts were dried under nitrogen and redissolved in 1 ml toluene. After washing (twice) with 2 ml 0.1 M NaHCO 3 and with water (once), toluene was evaporated under nitrogen. The residue containing thiohydantoin derivatives of the adducts was dissolved in 50 |il toluene for analysis by GC-MS.
Gas chromatography-mass spectrometry analysis
The samples were injected with a solid injector in a HP 5890 series II gas chromatograph coupled with a HP 5970 quadrupole mass spectrometer. The earner gas was helium. The chromatographic separation was made on a DB-5-ms fused silica capillary column (30mX0.32 mm, 0.12 mm phase thickness, Alltech Associates, USA). The source pressure was 0.005 Pa. The injector was maintained at 253°C and the interface at 270°C. The oven temperature was programmed at 5"C per min. from 150 to 250°C, followed by an increase of 10°C per min. to 300°C. The mass spectrometer was operated in the electron impact mode with an ionization energy of 70 eV. Selected ion monitoring used for the quantitation of/V-terminal valine styrene oxide adducts was carried out by monitoring the ions m/z 325 [loss of (C 6 H 3 )CHOCH] derived from the styrene oxide adduct and m/z 326 [loss of (C 6 D 3 )CHOCD] derived from the deuterated styrene oxide adduct.
DNA adduct determination
Cft-Styrene guanine adducts. The deep frozen mice tissues were shipped from Leuven to Prague. DNA was isolated from the nuclear pellet of liver, lungs and spleen and digested with micrococca] nuclease and spleen phosphodiesterase as described previously (22, 23) . DNA samples were subsequently treated with nuclease PI (24) . The phosphorylation reaction was carried out in Eppendorf plastic tubes in a total volume of 2.0 ill. To 1.0 nl of sample 1.0 Hi of labelling cocktail containing 1.0 HM [y-"P] ATP (3000 Ci/mmol, Amersham, UK), 1.0 HM non-radioactive ATP, 1.2 U T4 polynucleotide kinase (US Biochemical, USA), 40 mM bicine-NaOH, pH 9.6, 20 mM MgCl 2 , 2 mM spermidine and 20 mM dithiothreitol were added. The droplets were mixed and centrifuged, followed by incubation at 37°C for 45 min. Excess of ATP was removed by adding 20 pmol of 3'-TMP for 15 min and apyrase for an additional 25 min.
Each sample was analysed and quantitated with a parallel external standard, O 6 -(2-hydroxy-l-phenylethyl)-3'-dGMP, synthesized and characterized by us earlier (25) . All samples were analysed twice, some of them spiked with the internal C^-dGMP standard (4, 5) for the exact localization of O'-styrene adducts on the TLC plates. The samples were applied on PEI TLC plates (Macherey-Nagel, Germany). The whole chromatographic procedure, including magnet transfer and quantitation, was described by us earlier (4, 5, 26) . The present assay for O'-styrene guanine adducts does not distinguish individual regioisomers and diastereomers However, the major styrene-related spot comigrates with the above mentioned standard.
7-Alkylguanine adducts of styrene
The aliquots of DNA (5 |ig) from mice tissues along with the salmon testis DNA modified in vitro with SO, where the corresponding 7-alkylguanine level was 100 fmol/|ig DNA, were taken for DNA digestion. The DNA samples were incubated at 37*C with micrococcal nuclease (Sigma Chemicals Co., USA, 80 mU/ug) in 3.0 mM bicine, pH 9.0 and 0.2 mM CaCl 2 for 2 h followed by addition of spleen phosphodiesterase (Boehringer, Mannheim, FRG, 1.6 mU/ng) and 20 mM ammonium acetate, pH 5.0. The incubation was maintained for another 2 h at 37"C. The adduct enrichment was performed by applying DNA-digest into a strong anion exchange cartridge (1 ml, J.T. Baker, Holland) (27,28) pre-equilibrated with 5.0 mM ammonium formate, pH 5.2. 7-Alkylguanine adducts were eluted with the same buffer by centrifugation at 1600 r.p.m. The eluents (4 ml) were freeze-dried and taken up for -"P-postlabelling. The phosphorylation reaction was carried out in a total volume of 2.0 iil containing 2.0 HM [Y-32 P] ATP (3000 Ci/mmol, Amersham, UK), 40 mM bicine buffer, pH 9.6, 20 mM MgCl 2 , 2.0 mM spermidine and 6.0 U T4 polynucleotide kinase (US Biochemical Corp., USA). The mixture was incubated for 1 h at 37°C and nuclease P] (Boehringer, Mannheim, Germany) was added for 10 min. to convert bisphosphate nucleotides to 5'-monophosphate nucleotides. The 32 P-postlabelled mixture was applied to prewashed 10 x 20 cm PEI TLC plates (Macherey-Nagel, Germany) and developed with 0.1 M ammonium formate, pH 5.2, in the first dimension. For the development of the TLC plates in the second dimension 0.5 M ammonium formate, pH 5.2, and 50% n-propanol was used. The adduct levels were determined by cutting the area of the TLC plates corresponding to adduct spot on autoradiograms and counting for the Cerenkov radiation. The corresponding areas of the plates with depurinated controls were used for the background subtraction of radioactivity.
The TLC version of the 32 P-postlabelling assay is not suitable to separate individual isomenc and diastereomeric forms of 7-alkylguanines. The mixture of regioisomers was measured in our experiments. In vitro modified DNA with known N-7 alkylation level and 7-alkyl-3'-dGMP (8, 29) were used as external and internal standards for the determination of the N-l adduct recovery, calculated as described elsewhere (8) .
In vitro DNA treatment with styrene oxide Calf-thymus DNA (1 mg/ml, Sigma Chemicals Co., USA) was simultaneously treated for 24 h with styrene oxide (more than 97% pure, Aldrich-Chemie, FRG, final concentrations were 0.2, 0.4 and 0.6 mM) in 50 mM Tris-HCI buffer, pH 7.4 containing 30% methanol, and in culture medium (RPMI 1640, 150 IU/ml benzylpenicillin, 150 Hg/ml streptomycin, 0.3 mg/ml L-glutamine, 5% FCS, 5% HS). Styrene-specific O 6 -guanine adducts and 7-alkylguanine levels were analysed by 32 P-postlabelling as described above.
Statistical and mathematical methods
The statistical analysis was performed with SAS (statistical analysis system) using SAS/ASSIST software, version 6.08. The styrene-7,8-oxide concentration in the blood of the mice after i.p administration of styrene was simulated by the physiologic pharmacokinetic model (PBPK) of Csanady el al. (30) . The curves for the different doses were integrated to obtain the Area Under the Curve (AUC) of styrene oxide at each time point.
Correlations were calculated after transformation of the data. The Lineweaver-Burk model was used to correct for possible non-linearity resulting from the saturation kinetics.
Results
Incubation of styrene-7,8-oxide with calf thymus DNA
The incubation of calf thymus DNA with SO in a medium containing 50 mM Tris-HCI buffer and 30% methanol yielded higher (approximately two-fold) DNA adduct levels as compared with the biological medium (Table I) . In both media a significant dose-dependent increase of 7-alkylguanine formation was observed, while the C^-styrene guanine adduct levels remained similar in all tested concentrations. The N-7/0 6 ratio in the buffer/methanol medium was 6.5 ± 1.9, in the biological medium 9.1 ± 2.8. Figure 1 represents autoradiograms of 7-alkylguanine and C^-styrene guanine adducts formed in calf thymus DNA treated with 0.6 mM SO in buffer/methanol medium.
N-terminal valine, N-7-and O 6 '-guanine adducts in mice treated i.p. with styrene
Except for the control mouse, at all styrene doses /V-terminal valine adducts were higher than the detection limit (10 pmol/ g Hb) and ranged from 15 to 305 pmol/g Hb. The results as mean of three repeated GC-MS analyses per dose are presented in Table II .
Using the modified 32 P-postlabelling technique we detected the formation of styrene-specific N-7-and C^-guanine adducts 
Dose-response relationships for adduct formation
In the dose-range studied, for all adducts a clear dose-response relationship was observed (Table II, Figures 4 and 5) . The formation of spleen C^-guanine and TV-terminal valine adducts, the two least abundant adducts, is related linearly with the Prior to the exposure the TLC plates were cut in the middle to remove the background radioactivity, the upper parts of TLC plates containing 7-alkylguanines were exposed to X-ray films for 7 h at -80°C. For quantitation the spots comigrating with external and internal standards were taken. injected dose of styrene. The formation of liver and lung O 6 -guanine adducts and of all 7-alkylguanines shows a levelling off at higher doses. This was already observed at doses higher than 0.5 mmol/kg b.w., with the exception of lung 7-alkylguanines, where the levelling off was observed at 1.0 mmol/kg b.w.
Correlations between the adducts
All calculated correlations, summarized in Table III , were very strong. The highest correlation with the dose was found for C^-styrene guanine adducts in the liver (r = 0.99), since the dose-adduct curve follows practically exactly the theoretical curve calculated from the PBPK-model (Figure 7) . The difference between the theoretical modelling and the shape of the dose-adduct curve is most pronounced for C^-guanine adducts in the spleen, resulting in the lowest correlation (r = 0.86). All DNA adducts correlated very well with the amount of haemoglobin adducts formed (r = 0.93-1.00). Also all correlations among the DNA adducts were high (r 5= 0.90). 
Ratio between the different adducts and differences between tissues
In all tissues 7-alkylguanines were more abundant than O 6 -styrene guanine adducts, as could be expected from in vitro studies. The mean ratio between N-l-and C^-styrene guanine addlicts for liver, lung and spleen was 1.9, 1.6 and 7.8, respectively. The high N-l 10^ ratio for spleen can be attributed to the relatively low C^-guanine adduct levels at the doses up to 1.12 mmol/kg b.w.
The levels of both DNA adducts found in liver and spleen are very similar (Table II) . Surprisingly the highest DNA adduct levels were detected in the lung. In the lung, the O 6 -styrene guanine adducts were more abundant than in the liver and spleen at all doses. For doses higher than 1.0 mmol/kg b.w., the lung 7-alkylguanines were also the most abundant A/-7 adducts.
CBI values for 7-alkylguanines and Cfi-styrene guanine adducts in individual organs
N-l-and C^-styrene guanine adducts in individual organs were normalized to 1 mmol styrene per kg b.w. and the CBI values Qimol adducts/mol DNA nucleotide)/(mmol chemical/kg b.w.) were calculated (Table IV) .
Application of the PBPK model
The application of the PBPK model described by Csanady et al. (30) on the i.p. injected amount of styrene in this experiment shows that for the highest dose in this experiment (4.35 mmol/kg b.w.) it takes -10 h to metabolize all styrene to styrene oxide (Figures 6 and 7) . In our study, blood and tissues were taken after 3 h. At this time point styrene metabolism appears to have been completed for the lowest doses only (0-0.51 mmol/kg b.w.). A levelling off of both DNA adducts at the higher doses could be attributed to the lower effective concentrations of styrene oxide in particular tissues.
Discussion
The main binding sites of styrene oxide in DNA are positions N-l, TV 2 and O 6 of guanine. The proportions of N-1-, N 2 -and C^-adducts in double-stranded DNA are 74:22.3:3.7 as analysed by HPLC after in vitro incubation (3) . In the present study the ratio of N-l-and C^-guanine adduct formation determined by 32 P-postlabelling was markedly lower, probably due to the instability of 7-alkylguanines during the processing of the samples or due to relatively lower recovery of 7-alkylguanines by 32 P-postlabelling assay. An even lower ratio was obtained from the in vivo data. Furthermore, after intraperitoneal administration the low N-l/O 6 ratio in the lung and the liver contrasted with a relatively high ratio in the spleen. Apparently the ratio between N-l and C^-adducts is not constant, but varies depending on the general reaction conditions, on the persistence of the distinct adducts and on the efficiency of the repair.
In haemoglobin treated with radiolabelled SO, binding to the AMerminal valine ranges from 3.0 to 5.2% of the total radioactivity (9, 12) . //-Terminal valine adduct formation is less abundant compared with the formation of cysteine adducts (5.8%) and SO carboxylic acid esters (15.0%) (12, 16) . The lower adduct formation on //-terminal valine compared with 7-alkylguanines is in agreement with the study of Svensson et al. (31) . In this study after a 7 h exposure to propene (a compound with similar metabolism) the ratio between N-l-{2-hydroxypropyl)guanine and A'-(2-hydroxypropyl)valine formation in different mice tissues was established to be two to three. In long-term experiments this ratio may vary due to the persistence of N-terminal valine adducts throughout the lifetime of the erythrocyte, while 7-alkylguanines are likely to be removed due to spontaneous depurination or via repair process (32) .
Pharmacokinetic modelling revealed a non-linear increase of the AUC after 3 h. This appears to be in agreement with the levelling off of the DNA adduct formation at the higher doses. In mice and rats Osterman-Golkar et al. (14) observed a higher than proportional increase of the M-terminal valine adducts 6 and 24 h after the treatment. This could be explained by saturation of the SO detoxification, which was apparent in mice given styrene at the doses above 1.0 mmol/kg b.w. This phenomenon is not reflected in our results, possibly due to earlier sacrifice of mice after the treatment. However, it could be the reason why the levelling off at the high doses, especially for the least abundant adducts, is not so clearly pronounced as expected from the PBPK-model simulation. Surprisingly, the highest O 6 -and N-l guanine adduct levels were found in mice lungs after i.p. administration of styrene, although liver would be expected as the first pass organ. Several studies indicate that, either for direct acting compounds such as ethylene oxide (33) and benzyl chloride (34) or for compounds requiring metabolic activation such as benzo[a]pyrene (35) and cyclopenta[cJ]pyrene (36) , the extent of DNA adduct formation is similar in target and non-target tissues. The minor variations in the amounts of adducts formed are usually explained by physiological parameters such as tissue/ blood partition coefficients or by differences in the balance between activation and deactivation of the compound and by the repair of the adducts.
Although the main part of the biotransformation of styrene takes place in the liver (30) , the balance between the formation and the detoxification of SO may be different in the extrahepatic tissues. A study of De Waziers et al. (37) in humans and rats indicates that there are substantial differences in the organ distribution of the enzymes known to be involved in styrene metabolism (cytochrome P450, epoxide hydrolase and glutathione S-transferase). Also in mice, the activity of epoxide hydrolase has been found to be organ specific (38) , resulting in different rate of SO degradation. Other factors such as catalytic activity of oxyhaemoglobin and xanthine oxidase on the conversion of styrene to styrene oxide (39) could influence the concentration of SO present in the different tissues.
Reported DNA adduct levels, expressed as CBI values, are in general agreement with those values published by Cantoreggi and Lutz (11). However, in our study we detected for the first time specific N-l-and C^-guanine adducts in the short-term i.p. treatment. Previously (5) we found that C^-styrene guanine adducts were stable and persistent. Whether this was due to slow or inefficient repair remains unknown. Concerning 7-alkylguanines, these adducts may undergo either depurination (spontaneous or via excision repair) resulting in apurinic (AP) sites or imidazole-ring opening. However, only 'intact' 7-alkyl-dGMP adducts could be measured using the present method. Furthermore, biological consequences of ring-opened derivatives and AP sites have to be further studied. It has been suggested that AP sites, which are not repaired, could lead to the replicative bypass inserting adenine opposite to AP site (GC-TA transversion) (40,41). Although styrene and its principal metabolite, styrene-7,8-oxide, can be considered as weak mutagens, it is rather difficult to assess the risk associated with styrene exposure based on the short-term animal treatment.
Our present study clearly demonstrates DNA and haemoglobin adduct formation in mice treated i.p. with a single dose of styrene for a time period of 3 h. Although there are limitations in the experimental design (e.g. short duration of the experiment, small dose range), the ability to detect specifically N-l-and C^-styrene guanine adducts in vivo was the major achievement. Further studies should be devoted to the relationship between individual types of DNA adducts and Nterminal valine adducts and their biological consequences in subacute and chronic inhalation animal experiments in order to understand better these biomarkers, the use of which has recently been advocated in styrene-exposed humans.
